Corporate News Blog - Dermira Highlights Results from ARIDO Study for Assessment of Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis Patients

LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Dermira, Inc. (NASDAQ: DERM), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=DERM. The Company announced on October 13, 2017, positive results from ARIDO, a Phase-3 open-label extension study for the assessment of the long-term safety of topical, once-daily treatment with glycopyrronium tosylate in patients with primary axillary hyperhidrosis. For immediate access to our complimentary reports, including today's coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on DERM. Go directly to your stock of interest and access today's free coverage at: http://protraderdaily.com/optin/?symbol=DERM.

ARIDO Study and Findings

• ARIDO was designed to assess the long-term safety of glycopyrronium tosylate in adolescent and adult patients, aged nine and older, who participated in ATMOS-1 and ATMOS-2.

• ATMOS-1 and ATMOS-2 trials patients were enrolled in ARIDO and received additional 44 weeks of treatment with glycopyrronium tosylate. At the end of the 44-week treatment period, only 40.1% of patients completed ARIDO.

• Around 59.8% of patients reported one or more treatment-emergent adverse events (TEAE), most of which were considered mild or moderate in severity. Dry mouth, blurred vision, application site pain, common cold, and pupil dilation were the most frequently reported TEAEs observed.

• The incidence of TEAEs, including pre-specified anticholinergic TEAEs of interest, did not increase over time with longer duration of glycopyrronium treatment.

• An efficacy assessment conducted at the end of the treatment period in ARIDO suggests that patients who received glycopyrronium tosylate and completed the 44-week follow-up period maintained reduced sweat production compared to baseline and reported less bothersome sweating compared to baseline measures in ATMOS-1 and ATMOS-2.

ARIDO Findings Demonstrated the Tolerance of Glycopyrronium Tosylate

Eugene A. Bauer, M.D., Chief Medical Officer of Dermira, mentioned that the findings from the ARIDO study demonstrated that glycopyrronium tosylate is generally well-tolerated, with a side-effect profile that is consistent with earlier studies. The Company is also encouraged that the efficacy assessment conducted at the end of ARIDO suggests that patients continued to respond to topical treatment with glycopyrronium tosylate during the treatment extension period.

Positive Results from ATMOS-1 and ATMOS-2 Pivotal Phase-3 Clinical Trials

In June 2016, Dermira announced top-line results from its Phase-3 ATMOS-1 and ATMOS-2 pivotal trials for DRM04, a topical anticholinergic product candidate in development for patients with primary axillary hyperhidrosis. Both clinical trials evaluated the safety and efficacy of DRM04 compared to vehicle.

About Glycopyrronium Tosylate

Glycopyrronium tosylate is an anticholinergic agent formulation for once-daily, topical administration, designed to block sweat production by inhibiting the receptors responsible for sweat gland activation.

About Primary Axillary Hyperhidrosis

Hyperhidrosis is a condition characterized by excessive sweating. The sweating can affect just one specific area or the whole body. It tends to begin during adolescence. Primary axillary hyperhidrosis is the excessive underarm sweating, which cannot be managed by topical agents.

About Dermira, Inc.

Founded in 2010, Dermira is a biopharmaceutical Company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to millions of patients living with chronic skin conditions. The Company is based in Menlo Park, California.

Last Close Stock Review

On Friday, October 13, 2017, the stock closed the trading session at $29.03, slipping 1.36% from its previous closing price of $29.43. A total volume of 331.33 thousand shares have exchanged hands. Dermira's stock price advanced 9.42% in the last one month. The stock currently has a market cap of $1.22 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily